Bank of America
AVIR icon

Bank of America’s Atea Pharmaceuticals AVIR Stock Holding History

Bank of America’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$380K Sell
81,730
-23,910
-23% -$119K ﹤0.01% 5102
2026
Q1 		$568K Sell
105,640
-30,154
-22% -$138K ﹤0.01% 4828
2025
Q4 		$485K Sell
135,794
-177,850
-57% -$565K ﹤0.01% 4928
2025
Q3 		$910K Buy
313,644
+203,905
+186% +$696K ﹤0.01% 5391
2025
Q2 		$395K Buy
109,739
+49,078
+81% +$146K ﹤0.01% 5846
2025
Q1 		$181K Sell
60,661
-12,780
-17% -$39.9K ﹤0.01% 6231
2024
Q4 		$246K Buy
73,441
+13,902
+23% +$46.2K ﹤0.01% 6013
2024
Q3 		$199K Sell
59,539
-9,938
-14% -$36K ﹤0.01% 5998
2024
Q2 		$230K Buy
69,477
+2,411
+4% +$8.99K ﹤0.01% 5817
2024
Q1 		$271K Sell
67,066
-176,658
-72% -$691K ﹤0.01% 5719
2023
Q4 		$743K Buy
243,724
+147,292
+153% +$446K ﹤0.01% 5212
2023
Q3 		$289K Sell
96,432
-6,078
-6% -$20.7K ﹤0.01% 5681
2023
Q2 		$383K Sell
102,510
-34,013
-25% -$127K ﹤0.01% 5447
2023
Q1 		$457K Sell
136,523
-37,823
-22% -$153K ﹤0.01% 5425
2022
Q4 		$839K Buy
174,346
+45,867
+36% +$232K ﹤0.01% 4983
2022
Q3 		$731K Buy
128,479
+83,226
+184% +$637K ﹤0.01% 5108
2022
Q2 		$321K Buy
45,253
+7,740
+21% +$52.8K ﹤0.01% 5748
2022
Q1 		$271K Sell
37,513
-86,865
-70% -$590K ﹤0.01% 6272
2021
Q4 		$1.11M Buy
124,378
+88,748
+249% +$1.38M ﹤0.01% 5136
2021
Q3 		$1.25M Sell
35,630
-29,269
-45% -$812K ﹤0.01% 4866
2021
Q2 		$1.39M Buy
64,899
+40,589
+167% +$1.22M ﹤0.01% 4625
2021
Q1 		$1.5M Buy
24,310
+10,118
+71% +$684K ﹤0.01% 4493
2020
Q4 		$593K Buy
+14,192
New +$457K ﹤0.01% 4889

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bank of America's AVIR Position: Q2 2026 in Review

Bank of America reduced its Atea Pharmaceuticals (AVIR) stake by 23% in Q2 2026, selling an estimated $119K and leaving 81,730 shares worth $380K. The position accounts for ﹤0.01% of the portfolio, ranked #5102.

Bank of America first reported a position in AVIR in Q4 2020 and has held it in 23 quarters since. The position peaked at $1.5M in Q1 2021. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Bank of America held 81,730 shares of Atea Pharmaceuticals worth $380K as of Q2 2026.
  • Bank of America sold 23,910 Atea Pharmaceuticals shares in Q2 2026, an estimated $119K.
  • Atea Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #5102 holding.
  • Bank of America first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Bank of America's Atea Pharmaceuticals position peaked at $1.5M in Q1 2021.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.